CPMV · Mosaic Immunoengineering Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $15.9K | - | $16.0K | $16.0K | $15.8K | - | $39.6K | $60.7K | $67.3K | - |
| SG&A | $138.9K | - | $128.3K | $132.8K | $159.0K | - | $146.8K | $213.6K | $201.5K | - |
| Total Operating Expenses | $154.8K | - | $144.4K | $148.9K | $174.8K | - | $186.4K | $274.3K | $268.8K | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($154.8K) | - | ($144.4K) | ($148.9K) | ($174.8K) | - | ($186.4K) | ($274.3K) | ($268.8K) | - |
| Interest Expense | $2.5K | - | $2.5K | $2.5K | $0 | - | $0 | - | - | - |
| Income Tax | $0 | - | $0 | $2.4K | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($175.4K) | - | ($165.4K) | ($172.0K) | ($181.3K) | - | ($186.7K) | ($293.7K) | ($288.5K) | - |
| EPS - Basic | ($0.02) | - | ($0.02) | ($0.02) | ($0.03) | - | ($0.03) | ($0.04) | ($0.04) | - |
| EPS - Diluted | ($0.02) | - | ($0.02) | ($0.02) | ($0.03) | - | ($0.03) | ($0.04) | ($0.04) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72 | $3.6K | $31.8K | $53.6K | $85.9K | $115.0K | $5.7K | $3.7K | $65.0K | $156.2K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $167.1K | $132.8K | $133.8K | $133.8K | $138.1K | $134.9K | $143.6K | $125.0K | $129.5K | $118.5K |
| Current Assets | $9.8K | $19.9K | $55.3K | $57.7K | $97.8K | $141.6K | $40.0K | $12.3K | $79.0K | $179.5K |
| Total Assets | $9.8K | $19.9K | $55.3K | $57.7K | $97.8K | $141.6K | $40.0K | $12.3K | $79.0K | $179.5K |
| Current Liabilities | $6.18M | $6.03M | $5.91M | $5.77M | $5.66M | $5.54M | $5.30M | $5.11M | $4.90M | $4.73M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $7.66M | $7.50M | $7.36M | $7.20M | $7.07M | $6.93M | $6.68M | $6.46M | $6.23M | $6.05M |
| Stockholders' Equity | ($7.65M) | ($7.48M) | ($7.31M) | ($7.14M) | ($6.97M) | ($6.79M) | ($6.64M) | ($6.45M) | ($6.15M) | ($5.87M) |
| Retained Earnings | ($9.70M) | ($9.53M) | ($9.36M) | ($9.19M) | ($9.02M) | ($8.84M) | ($8.69M) | ($8.50M) | ($8.20M) | ($7.92M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.5K) | - | - | - | ($29.1K) | - | - | - | ($91.1K) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | $0 | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -1784.2% | - | -299.0% | -298.1% | -185.4% | - | -467.4% | -2392.4% | -365.4% | - |
| Return on equity | 2.3% | - | 2.3% | 2.4% | 2.6% | - | 2.8% | 4.6% | 4.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0.00 | 0.02 | 0.04 |
| Quick ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0.00 | 0.02 | 0.04 |
| Cash ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.00 | 0.00 | 0.01 | 0.03 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -62.7x | - | -57.3x | -59.7x | - | - | - | - | - | - |
| Equity multiplier | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | -0.00 | -0.01 | -0.03 |
| Liabilities / Assets | 779.53 | 377.02 | 133.14 | 124.77 | 72.27 | 48.94 | 167.09 | 526.24 | 78.95 | 33.70 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 11.4% | - | 22.6% | 45.7% | 35.0% | - | 40.2% | 22.2% | 63.1% | - |
| Net income growth (YoY) | 3.3% | - | 11.4% | 41.4% | 37.1% | - | 44.0% | - | 27.7% | - |
| EPS growth (YoY) | 33.3% | - | 33.3% | 50.0% | 25.0% | - | 40.0% | - | 63.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -9.8% | -10.1% | -10.1% | -10.7% | -13.2% | -15.6% | -18.9% | -22.7% | -16.6% | -20.2% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Mosaic ImmunoEngineering Inc. against the 5 most active filers in the same SIC group.